Morgan Stanley lowered the firm’s price target on Alnylam (ALNY) to $268 from $284 and keeps an Equal Weight rating on the shares. The firm is ...

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc.

Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis, Alnylam has got the go-ahead for a second – Amvuttra – which has a simpler ...

Vutrisiran is already approved as Amvuttra to treat rare disease hereditary ATTR amyloidosis, so approval in Stargardt disease would prompt the pricing negotiation mechanism. Alnylam's earlier ...

President Trump’s newly announced tariff policy has done more than just push the stock markets deeper into correction territory — the sudden ...

Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Alnylam ...

Explore Alnylam Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ALNY. Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff ...

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated ...